Longtime liberal advocate to lead generics industry group

The Generic Pharmaceutical Association is about to get a new lead lobbyist: Ralph Neas, whom the New York Times characterizes as "a longtime advocate for liberal causes." Neas told the Times he's "anxious to tell" policy makers about the generics industry's efforts in controlling healthcare costs. Report

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.